---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-015281"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:31:44.292057+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q3 net loss $33.5M; pemvidutide shows liver fat reduction to undetectable levels

## Summary
- Net loss of $33.5M ($0.81 per share) for Q3 2021, up from $17.8M in Q3 2020.
- Cash and short-term investments totaled $199.9M at Sept 30, 2021; revenue fell to $0.2M from $2.9M.
- Phase 1 pemvidutide data: mean weight loss up to 10.3% at 1.8 mg at week 12 without dose titration.
- MRI-PDFF analysis in 5 subjects with hepatic steatosis showed liver fat fell to undetectable levels within 6 weeks (≥90% reduction).
- Phase 2 obesity and NASH trials expected to start in 2022; IND for obesity by year-end 2021.

## SEC filing metadata
- accession: 0001558370-21-015281
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837021015281/0001558370-21-015281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837021015281/alt-20211109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-015281
- JSON: https://secwatch.observer/filing/0001558370-21-015281.json
- Plain text: https://secwatch.observer/filing/0001558370-21-015281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.